The delay problem
In studies from multiple countries — including India — the average time between the onset of erectile dysfunction and seeking medical evaluation is three to five years. The reasons are consistent: stigma, the belief that the condition will resolve spontaneously, reluctance to discuss the topic with a doctor, and the normalisation of ED as an inevitable consequence of aging.
None of these reasons holds up to clinical scrutiny.
ED is not inevitable with age. While testosterone levels and vascular function naturally change over the decades, ED that significantly impacts sexual function at any age is a clinical condition — not a character flaw, and not a fixed consequence of growing older.
ED is unlikely to resolve without evaluation and management of contributing factors. The vascular and hormonal contributors to organic ED are progressive, not self-limiting. Earlier evaluation means a broader range of intervention options, more reversible contributing factors, and lower cumulative cardiovascular risk.
When evaluation is warranted
There is no threshold below which ED is "not worth" discussing with a doctor. But several presentations suggest that evaluation is particularly important:
New onset in a man under 45. ED in younger men is more likely to have a reversible contributing factor — psychogenic, hormonal, or lifestyle-related — and is more likely to respond fully to appropriate management. Younger men also have a longer time horizon for cardiovascular risk modification.
Progressive worsening over months. Gradual progression suggests an organic component. Sudden onset suggests psychological or medication-related causes.
Associated with reduced libido. The combination of ED and low libido suggests a hormonal component, particularly testosterone deficiency, that requires specific evaluation.
In the presence of metabolic risk factors. Hypertension, diabetes, dyslipidaemia, obesity, and smoking all substantially increase the probability of an organic, vascular cause. In a man with multiple metabolic risk factors, ED should be treated as a cardiovascular risk indicator.
When it is affecting quality of life or relationship health. This is sufficient. Erectile dysfunction affects self-esteem, intimate relationships, and mental health. The impact on quality of life is a legitimate reason to seek evaluation, independent of any underlying condition.
What happens at the first evaluation
A first consultation for ED typically involves a structured but private conversation covering:
- When the difficulty started and how it has progressed
- Whether it is consistent across all contexts or varies (different partners, different situations, morning vs. partnered erections)
- Current medications, medical history, and metabolic risk factors
- Relationship context and any relevant psychosocial stressors
This is followed by a physical examination and targeted blood tests as described in the ED evaluation article. The evaluation is not an interrogation — it is a clinical conversation aimed at understanding which of the multiple potential contributors to ED are present in this specific patient.
The privacy concern
A significant barrier for Indian men is the concern that seeking evaluation for ED will be stigmatising — that information will be visible on their health records, communicated to family members, or visible to insurers or employers.
Under India's Digital Personal Data Protection Act (2023), health data is classified as sensitive personal data and cannot be shared without explicit informed consent. A telemedicine consultation for ED creates a protected clinical record, not a disclosure. Notifications and communications from a responsible platform use generic language — not condition-specific.
The privacy of the consultation is a structural feature of responsible telemedicine, not an aspiration.
A note on self-treatment
Several categories of self-treatment are pursued by Indian men with ED: online pharmacies for PDE5 inhibitors without evaluation, herbal preparations making unlicensed claims, and gym-community testosterone protocols. Each carries different risks:
Unsupervised PDE5 inhibitors are contraindicated with certain medications (particularly nitrates used in cardiovascular disease) and can cause dangerous hypotension. More importantly, they mask rather than address the underlying condition — including cardiovascular disease.
Herbal preparations marketed for ED in India are regulated under Schedule J, which prohibits claims of treatment for sexual impotence. A product making such claims is either legally non-compliant or making them through euphemism.
Unsupervised testosterone protocols — common in gym culture — can suppress the body's own testosterone production, impair fertility, and create long-term endocrine disruption. Testosterone is a Schedule H medication in India, appropriately requiring medical supervision.
The appropriate starting point is a medical evaluation, not a product.